Article
Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice.
Gut - 1 Dec 2016
Vercauteren Koen, Brown Richard J P, Mesalam Ahmed Atef, Doerrbecker Juliane, Bhuju Sabin, Geffers Robert, Van Den Eede Naomi, McClure C Patrick, Troise Fulvia, Verhoye Lieven, Baumert Thomas, Farhoudi Ali, Cortese Riccardo, Ball Jonathan K, Leroux-Roels Geert, Pietschmann Thomas, Nicosia Alfredo, Meuleman Philip
Abstract excerpt
OBJECTIVE: Direct-acting antivirals (DAAs) inhibit hepatitis C virus (HCV) infection by targeting viral proteins that play essential roles in the replication process. However, selection of resistance-associated variants (RAVs) during DAA therapy has been a cause of therapeutic failure. In this study, we wished to address whether such RAVs could be controlled by the co-administration of host-targeting entry...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.